Marshall Wace
STLNW

Marshall Wace’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Marshall Wace’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-62,492
Closed -$108K – 2177
2020
Q3 		$106K Buy
+62,492
New +$103K ﹤0.01% 1514

Other funds holding STLNW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Marshall Wace's STLNW Position: Q4 2020 in Review

Marshall Wace sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2020, closing a stake of 62,492 shares — an estimated $108K sold.

Marshall Wace first reported a position in STLNW in Q3 2020 and held it in 1 quarter. The position peaked at $106K in Q3 2020. 25 funds tracked by Wall St. Rank hold STLNW as of Q4 2020.

  • Marshall Wace reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace sold 62,492 Starling Oncology, Inc. Warrant shares in Q4 2020, an estimated $108K.
  • Marshall Wace first reported a position in Starling Oncology, Inc. Warrant in Q3 2020 and held it in 1 quarter.
  • Marshall Wace's Starling Oncology, Inc. Warrant position peaked at $106K in Q3 2020.
  • 25 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2020.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.